Cellosaurus PC-14 (CVCL_1640)

Cell line name PC-14
Synonyms PC14
Accession CVCL_1640
Resource Identification Initiative To cite this cell line use: PC-14 (RRID:CVCL_1640)
Comments Problematic cell line: Contaminated. Shown to be a PC-9 derivative.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
From: Immuno-Biological Laboratories (IBL); Tokyo; Japan.
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: EGFR p.Glu746_Ala750del (from parent cell line).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Lung adenocarcinoma (NCIt: C3512)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_B260 (PC-9)
Children: CVCL_9W69 (PC-14-PM4); CVCL_9W71 (PC14Br); CVCL_J032 (PC14HM); CVCL_9W70 (PC14PE6)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; ECACC; PubMed=11416159

Markers:
AmelogeninX
CSF1PO11
D13S3178
D16S5399
D18S5115
D21S1129,30
D5S81811
D7S82010,11 (Cosmic-CLP)
10 (ECACC; PubMed=11416159)
D8S117911,15
FGA23,25
TH017
TPOX11
vWA17
Web pages http://www.brc.riken.jp/lab/cell/english/rcb0446_announce.shtml
Publications

PubMed=4094096
Lee Y.-C., Saijo N., Sasaki Y., Takahashi H., Sakurai M., Ishihara J., Hoshi A., Chen K.-M., Hamburger A.W.
Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9, PC-13 and PC-14) and how they influence the results of test for chemosensitivity to cisplatin in the human tumor clonogenic assay.
Jpn. J. Clin. Oncol. 15:637-644(1985)

PubMed=11005564; DOI=10.1038/sj.neo.7900094
Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M., Yokota J.
Mutation and expression of the DCC gene in human lung cancer.
Neoplasia 2:300-305(2000)

PubMed=14581340
Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.
TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.
Clin. Cancer Res. 9:4705-4713(2003)

PubMed=15185009; DOI=10.1007/s00262-004-0533-9
Yamaji H., Iizasa T., Koh E., Suzuki M., Otsuji M., Chang H., Motohashi S., Yokoi S., Hiroshima K., Tagawa M., Nakayama T., Fujisawa T.
Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer.
Cancer Immunol. Immunother. 53:786-792(2004)

PubMed=15746151; DOI=10.1093/hmg/ddi092
Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M., Hirohashi S., Inazawa J., Imoto I.
Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.
Hum. Mol. Genet. 14:997-1007(2005)

PubMed=19472407; DOI=10.1002/humu.21028
Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
A gene-alteration profile of human lung cancer cell lines.
Hum. Mutat. 30:1199-1206(2009)

PubMed=22313637; DOI=10.4161/cbt.19238
Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A., Igishi T., Burioka N., Nanba E., Shimizu E.
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Cancer Biol. Ther. 13:369-378(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25120651; DOI=10.3892/ol.2014.2234
Suzuki M., Ikeda K., Shiraishi K., Eguchi A., Mori T., Yoshimoto K., Shibata H., Ito T., Baba Y., Baba H.
Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer.
Oncol. Lett. 8:1025-1030(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections ECACC; 90071810
RCB; RCB0446 - Discontinued
Cell line databases/resources CLDB; cl3880
CCLE; PC14_LUNG
CGH-DB; 205-1
CGH-DB; 9169-4
Cosmic-CLP; 753608
GDSC; 753608
LINCS_LDP; LCL-1656
Ontologies BTO; BTO:0002877
CLO; CLO_0008394
EFO; EFO_0002844
Chemistry resources ChEMBL-Cells; CHEMBL3307306
ChEMBL-Targets; CHEMBL614140
Gene expression databases GEO; GSM827410
GEO; GSM887505
GEO; GSM888587
GEO; GSM1670338
Polymorphism and mutation databases Cosmic; 753608
Cosmic; 801577
Cosmic; 876138
Cosmic; 897744
Cosmic; 932924
Cosmic; 946060
Cosmic; 1239897
Cosmic; 1571737
Cosmic; 1656894
Cosmic; 1995612
Cosmic; 2125282